The REinfection in COVID-19 Estimation of Risk (RECOVER) study: Reinfection and serology dynamics in a cohort of Canadian healthcare workers.
COVID-19
SARS-CoV-2
prospective studies
reinfection
serology
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
22
04
2022
received:
18
04
2022
accepted:
25
04
2022
pubmed:
6
5
2022
medline:
4
8
2022
entrez:
5
5
2022
Statut:
ppublish
Résumé
Understanding the immune response to natural infection by SARS-CoV-2 is key to pandemic management, especially in the current context of emerging variants. Uncertainty remains regarding the efficacy and duration of natural immunity against reinfection. We conducted an observational prospective cohort study in Canadian healthcare workers (HCWs) with a history of PCR-confirmed SARS-CoV-2 infection to (i) measure the average incidence rate of reinfection and (ii) describe the serological immune response to the primary infection. Our cohort comprised 569 HCWs; median duration of individual follow-up was 371 days. We detected six cases of reinfection in absence of vaccination between August 21, 2020, and March 1, 2022, for a reinfection incidence rate of 4.0 per 100 person-years. Median duration of seropositivity was 415 days in symptomatics at primary infection compared with 213 days in asymptomatics (p < 0.0001). Other characteristics associated with prolonged seropositivity for IgG against the spike protein included age over 55 years, obesity, and non-Caucasian ethnicity. Among unvaccinated healthcare workers, reinfection with SARS-CoV-2 following a primary infection remained rare.
Sections du résumé
BACKGROUND
Understanding the immune response to natural infection by SARS-CoV-2 is key to pandemic management, especially in the current context of emerging variants. Uncertainty remains regarding the efficacy and duration of natural immunity against reinfection.
METHODS
We conducted an observational prospective cohort study in Canadian healthcare workers (HCWs) with a history of PCR-confirmed SARS-CoV-2 infection to (i) measure the average incidence rate of reinfection and (ii) describe the serological immune response to the primary infection.
RESULTS
Our cohort comprised 569 HCWs; median duration of individual follow-up was 371 days. We detected six cases of reinfection in absence of vaccination between August 21, 2020, and March 1, 2022, for a reinfection incidence rate of 4.0 per 100 person-years. Median duration of seropositivity was 415 days in symptomatics at primary infection compared with 213 days in asymptomatics (p < 0.0001). Other characteristics associated with prolonged seropositivity for IgG against the spike protein included age over 55 years, obesity, and non-Caucasian ethnicity.
CONCLUSIONS
Among unvaccinated healthcare workers, reinfection with SARS-CoV-2 following a primary infection remained rare.
Identifiants
pubmed: 35510653
doi: 10.1111/irv.12997
pmc: PMC9343327
doi:
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
916-925Subventions
Organisme : CIHR
ID : VR2-172712
Pays : Canada
Informations de copyright
© 2022 The Authors. Influenza and Other Respiratory Viruses published by John Wiley & Sons Ltd.
Références
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Clin Infect Dis. 2021 Oct 5;73(7):1323-1324
pubmed: 33503228
Eur J Clin Invest. 2021 May;51(5):e13537
pubmed: 33675046
Lancet Public Health. 2021 May;6(5):e335-e345
pubmed: 33857453
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Lancet Infect Dis. 2022 Jun;22(6):821-834
pubmed: 35298900
Lancet Respir Med. 2022 Feb;10(2):e17
pubmed: 34929158
EClinicalMedicine. 2021 May;35:100861
pubmed: 33937733
Clin Infect Dis. 2021 Nov 16;73(10):1882-1886
pubmed: 33718968
Lancet. 2021 Apr 17;397(10283):1421-1423
pubmed: 33844964
Int J Surg. 2020 Jun;78:185-193
pubmed: 32305533
J Public Health (Oxf). 2022 Jun 27;44(2):e315-e316
pubmed: 34137434
EBioMedicine. 2021 Sep;71:103561
pubmed: 34455390
Lancet Infect Dis. 2021 Jan;21(1):3-5
pubmed: 33058796
Eur J Clin Invest. 2021 Apr;51(4):e13520
pubmed: 33583018
Lancet. 2021 Apr 17;397(10283):1459-1469
pubmed: 33844963
Science. 2022 May 6;376(6593):eabn4947
pubmed: 35289632
Clin Infect Dis. 2022 Mar 1;74(4):719-722
pubmed: 33993225
J Infect. 2021 Jun;82(6):e4-e5
pubmed: 33839184
J Infect. 2021 Apr;82(4):e29-e30
pubmed: 33373652
Lancet. 2021 Mar 27;397(10280):1204-1212
pubmed: 33743221
J Med Virol. 2021 Sep;93(9):5228-5230
pubmed: 33942326
Influenza Other Respir Viruses. 2022 Sep;16(5):916-925
pubmed: 35510653
Clin Infect Dis. 2021 Oct 5;73(7):e1830-e1840
pubmed: 33315061